Old Web
English
Sign In
Acemap
>
authorDetail
>
Kim Paes
Kim Paes
Takeda Pharmaceutical Company
Lanadelumab
Pediatrics
Hereditary angioedema
Medicine
open label
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies
2021
The Journal of Allergy and Clinical Immunology
Timothy J. Craig
Rafael H. Zaragoza-Urdaz
John Anderson
Huamin Li
Kim Paes
Clinical Scientist
Hong Ren
Salome Juethner
Show All
Source
Cite
Save
Citations (0)
Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE)
2021
The Journal of Allergy and Clinical Immunology
Maureen Watt
Marcus Maurer
Giovanna Devercelli
Kim Paes
Antoine Regnault
Julliette Meunier
Laurine Bunod
Marc A. Riedl
William R. Lumry
Show All
Source
Cite
Save
Citations (0)
Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Long-Term Prophylaxis Use: Interim Results From the HELP Open-Label Extension Study
2020
The Journal of Allergy and Clinical Immunology
Kim Paes
Timothy J. Craig
Jonathan A. Bernstein
Hilary Longhurst
Emel Aygören Pürsün
Christina Nurse
Bruce L. Zuraw
Joshua J. Jacobs
Show All
Source
Cite
Save
Citations (0)
1